Kivu Biosciences-preview

Kivu-biosciences

Kivu Biosciences

Private

San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.kivubioscience.com

Last Round

Series A

Oct 28, 2024

Total Funding Raised

$92M

Momentum Score

25 /100

Company Overview

Kivu Biosciences is a biotechnology company focused on the development of cancer therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCcancer therapeuticsADC platformsolid tumor treatmentnext-generation ADCssite-specific conjugationstable ADCstherapeutic windowADC safetyarmed antibodiespreclinical biotechpayload deliverydrug licensingbiopharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kivu Biosciences Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kivu Biosciences Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Oct 28, 2024

View all Funding Rounds

Key People

Founding team and executive leadership

Mohit Trikha

President COO

Executive Team

Kivu Biosciences Investors

Notable investors and investment history

Investor	Rounds
Gimv	Series A
M Ventures	Series A
HealthCap	Series A
Novo Holdings	Series A
BioGeneration Ventures	Series A
Red Tree Venture Capital	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 22, 2026
Grew 20% QoQ, from 20 to 24 employees.
Apr 15, 2026
Preclinical data on next-gen ADC programs to be presented at AACR 2026.

View all signals

Kivu Biosciences Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Kivu Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kivu Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California

Employee Range24

Year Founded2024

Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.